top of page
Cost-effectiveness of prophylaxis with recombinant versus plasma-derived VWF in severe von Willebrand disease in the US
Waldron C, Ito S, Wang D, Allen C, Viswanathan G, Bona RD, Cuker A, Goshua G
Blood
April
2024
Cost-effectiveness of adding quizartinib to induction chemotherapy for patients with FLT3-mutant acute myeloid leukemia
Bewersdorf JP, Patel KK, Shallis RM, Podoltsev NA, Kewan T, Stempel J, Mendez L, Stahl M, Stein EM, Huntington SF, Goshua G* and Zeidan AM*
Leukemia & Lymphoma
April
2024
Decreasing alloimmunization-specific mortality in sickle cell disease in the United States: Cost-effectiveness of a shared transfusion resource
Ito S, Pandya A, Hauser RG, Krishnamurti L, Stites E, Tormey C, Krumholz HM, Hendrickson JE, Goshua G
American Journal of Hematology
April
2024
Cost-effectiveness of bevacizumab therapy in the care of patients with hereditary hemorrhagic telangiectasia
Wang D, Ito S, Waldron C, Butt A, Zhang E, Krumholz H, Al-Samkari H* and Goshua G*
Blood Advances
March
2024
Cost-effectiveness of rapid vs. in-house vs. send-out ADAMTS13 testing for immune thrombotic thrombocytopenic purpura
Allen C, Ito S, Butt A, Purcell A, Richmond R, Tormey CA, Krumholz H, Cuker A, Goshua G
Blood Advances
March
2024
Splenectomy reappraised: Bridging the gap in immune cytopenia treatment paradigms
Waldron C and Goshua G
Journal of Internal Medicine
February
2024
Featured Publications (5)
All Selected Publications
Cost-effectiveness of adding quizartinib to induction chemotherapy for patients with FLT3-mutant acute myeloid leukemia
Bewersdorf JP, Patel KK, Shallis RM, Podoltsev NA, Kewan T, Stempel J, Mendez L, Stahl M, Stein EM, Huntington SF, Goshua G* and Zeidan AM*
Leukemia & Lymphoma
2024
April
Decreasing alloimmunization-specific mortality in sickle cell disease in the United States: Cost-effectiveness of a shared transfusion resource
Ito S, Pandya A, Hauser RG, Krishnamurti L, Stites E, Tormey C, Krumholz HM, Hendrickson JE, Goshua G
American Journal of Hematology
2024
April
Prophylactic weekly efanesoctocog alfa versus standard-care factor VIII in people living with severe hemophilia A: a cost-effectiveness analysis
Ito S, Potnis KC, Harvey JP, Sra M, Bewersdorf JP, Bona RD, Krumholz HM, Cuker A, Pandya A, Goshua G.
Annals of Internal Medicine
2025
June
FEATURED
Cost-effectiveness of Lynch syndrome screening in colorectal cancer: universal germline vs sequential screening
Ito S, Xicola RM, Sra M, Potnis KC, Singh V, Gershkovich P, Stites E, Gibson J, Krumholz HM, Llor X, Goshua G
Clinical Gastroenterology & Hepatology
2025
April
FEATURED
Cost-effectiveness of ferritin screening thresholds for iron deficiency in reproductive-age women
Wang D, Sra M, Glaeser-Khan S, Wang DY, Moshashaian-Asl R, Ito S, Cuker A, Goshua G
American Journal of Hematology
2025
April
FEATURED
Cost-effectiveness of iptacopan for paroxysmal nocturnal hemoglobinuria
Ito S*, Chetlapalli K*, Wang D, Potnis KC, Richmond R, Krumholz H, Lee AI, Cuker A, Goshua G.
Blood
2025
January
FEATURED
Decreasing alloimmunization-specific mortality in sickle cell disease in the United States: Cost-effectiveness of a shared transfusion resource
Ito S, Pandya A, Hauser RG, Krishnamurti L, Stites E, Tormey C, Krumholz HM, Hendrickson JE, Goshua G
American Journal of Hematology
2024
April
FEATURED
RECOGNITIONS:
Gap: Supporting the mission of the 501(c)(3) Alloantibody Exchange www.alloantibody.org. 2022 ASH Press Program Selection.
PRACTICAL IMPACT:
Publications
bottom of page